RealNews

Glaxo has bird flu ‘breakthrough’

UK drugs firm GlaxoSmithKline believes it has developed a vaccine for the H5N1 deadly strain of bird flu that may be capable of being mass produced by 2007. The vaccine has proved effective at two doses of 3.8 micrograms during clinical trials in Belgium, BBC business editor Robert Peston has learned. It is the size of the dose that is highly significant, Glaxo explained. Full Story

OODA Analyst

OODA Analyst

OODA is comprised of a unique team of international experts capable of providing advanced intelligence and analysis, strategy and planning support, risk and threat management, training, decision support, crisis response, and security services to global corporations and governments.